期刊文献+

Bcl-2抑制剂S1通过内质网途径对小鼠黑色素瘤B16细胞移植瘤生长抑制作用 预览 被引量:1

Inhibitory Effects of Bcl-2 inhibitor S1 on Growth of mouse melanoma B16 Cell Xenografts mediated by Endoplasmic Reticulum Stress
在线阅读 下载PDF
收藏 分享 导出
摘要 目的建立小鼠黑色素瘤B16细胞移植瘤模型,探讨Bcl-2抑制剂S1对其生长的影响及其作用机制。方法将小鼠黑色素瘤B16细胞种植至小鼠腋下,14天后开始用药物治疗,隔天给药。实验分为对照组、S1组(0.6mg/kg),28天后处死。测量移植瘤的重量。并采用免疫组化法检测内质网应激、凋亡相关蛋白等蛋白表达水平的变化。结果与对照组相比,S1处理组能够明显降低移植瘤体积、重量,差异有统计学意义(P〈0.05);应用S1后移植瘤中Caspase3表达增加、抗凋亡蛋白Bcl-2表达减少、内质网应激相关蛋白GRP78以及内质网应激-凋亡相关蛋白CHOP表达水平明显上升,差异有统计学意义(P〈0.05)。结论小分子化合物S1可以抑制小鼠黑色素瘤B16细胞移植瘤的生长,其作用途径可能同内质网凋亡信号通路相关。 Objective This study was to establish tranplanted mouse melanoma models and investigate the inhibitory effects of Bcl-2inhibitor S1 on them.Methods Mouse melanoma B16 cells were implanted into the mice under the armpit.The mice were treated with S1 every two days after 14 days,and were killed 28 days latter.Tumor volume and weight were measured.The experssion of proteins involed in Endoplasmic Reticulum Stress(ERS)and apoptosis were observed by immunohistochemistry.Results Compared with the control group,the average tumor volume was smaller and the average tumor weight were lighter in S1group;the average experssion of Capase3 was higher,the experssion of Bcl-2was lower,the experssion of proteins relating with ERS-GRP78 and CHOP were higher.Conclusion S1 inhibits the growth of B16 cells xenografts in mice,ERS may be related to the process.
作者 李亚平 吴瑶 颜晓羽 薛亚楠 路圣垚 苏静 LI Ya-ping , WU Yao, YAN Xiao-yu, et al. (People ' s Hospital of Jilin Province, Changchun 130021,China)
出处 《中国实验诊断学》 2016年第11期1805-1808,共4页 Chinese Journal of Laboratory Diagnosis
基金 国家自然科学基金面上项目(81472419 81272876)
关键词 内质网应激 细胞凋亡 Bcl-2抑制剂 Endoplasmic Reticulum Stress apoptosis Bcl-2 inhibitor
作者简介 通讯作者
  • 相关文献

参考文献3

二级参考文献77

  • 1Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J]. J Clin Oncol,2006,24( 1 ) :25 -35. 被引量:1
  • 2Gajewski TF, Niedzwiecki D, Johnson J, et al. Phase Ⅱ study of the farnesyltransferase inhibitor R115777 in advanced melanoma : CALGB 500104 [ J ]. J Clin Oncol, 2006,24( 18 Suppl) :8014. 被引量:1
  • 3Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase Ⅱ randomised discontinuation trial analysis [J]. Br J Cancer,2006,95 (5) :581 -586. 被引量:1
  • 4Flaherty KT, Schiller J, Schuchter LM, et al. A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel [J]. Clin Cancer Res ,2008,14 ( 15 ) : 4836 - 4842. 被引量:1
  • 5Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity [J]. Proc Natl Acad Sci USA, 2008,105 ( 8 ) : 3041 - 3046. 被引量:1
  • 6Fecher LA, Amaravadi R, Schuchter LM. Effectively targeting BRAF in melanoma: a formidable challenge [J]. Pigment Cell Melanoma Res,2008,21 (4) : 410 - 411. 被引量:1
  • 7Haass NK, Sproesser K, Nguyen TK, et al. The mitogenactivated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel [J]. Clin Cancer Res, 2008,14( 1 ) : 230 -239. 被引量:1
  • 8Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmaeokinetic and pharmaeodynamic study of the oral, small-molecule mitogen-activated protein kinase kiuase I/ 2 inhibitor AZD6244 ( ARRY-142886 ) in patients with advancedcancers [J]. J Clin Oncol,2008,26 ( 13 ) : 2139 - 2146. 被引量:1
  • 9Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a Phase Ⅱ trial of the California Cancer Consortium [ J ]. Cancer,2005,104 (5) : 1045 - 1048. 被引量:1
  • 10Thallinger C, Poeppl W, Pratscher B, et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model [J]. Pharmacology,2007,79(4) : 207-213. 被引量:1

共引文献28

同被引文献3

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈